Cargando…

Prostate cancer marker panel with single cell sensitivity in urine

BACKGROUND: Over one million men undergo prostate biopsies annually in the United States, a majority of whom due to elevated serum PSA. More than half of the biopsies turn out to be negative for prostate cancer (CaP). The limitations of both the PSA test and the biopsy procedure have led to the deve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nickens, Kristen P., Ali, Amina, Scoggin, Tatiana, Tan, Shyh‐Han, Ravindranath, Lakshmi, McLeod, David G., Dobi, Albert, Tacha, David, Sesterhenn, Isabell A., Srivastava, Shiv, Petrovics, Gyorgy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2015
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4424114/ https://www.ncbi.nlm.nih.gov/pubmed/25808739 http://dx.doi.org/10.1002/pros.22981

Ejemplares similares

Methylation of the PMEPA1 gene, a negative regulator of the androgen receptor in prostate cancer
por: Sharad, Shashwat, et al.
Publicado: (2014)

Autoantibodies against oncogenic ERG protein in prostate cancer: potential use in diagnosis and prognosis in a panel with C-MYC, AMACR and HERV-K Gag
por: Rastogi, Anshu, et al.
Publicado: (2016)

Functional antagonism of TMPRSS2-ERG splice variants in prostate cancer
por: Rastogi, Anshu, et al.
Publicado: (2014)

Quantitative Expression of TMPRSS2 Transcript in Prostate Tumor Cells Reflects TMPRSS2-ERG Fusion Status
por: Mwamukonda, Kuwong, et al.
Publicado: (2009)

Silencing of PMEPA1 accelerates the growth of prostate cancer cells through AR, NEDD4 and PTEN
por: Li, Hua, et al.
Publicado: (2015)

Molecular profiling of radical prostatectomy tissue from patients with no sign of progression identifies ERG as the strongest independent predictor of recurrence
por: Yan, Wusheng, et al.
Publicado: (2019)

Low Frequency of the ERG Oncogene Alterations in Prostate Cancer Patients from India
por: Rawal, Sudhir, et al.
Publicado: (2013)

Association of germline genetic variants with TMPRSS2-ERG fusion status in prostate cancer
por: Kohaar, Indu, et al.
Publicado: (2020)

Oncogenic activation of ERG: A predominant mechanism in prostate cancer
por: Sreenath, Taduru L, et al.
Publicado: (2011)

Genetic and Molecular Differences in Prostate Carcinogenesis between African American and Caucasian American Men
por: Farrell, James, et al.
Publicado: (2013)

Focal p53 protein expression and lymphovascular invasion in primary prostate tumors predict metastatic progression
por: Gesztes, William, et al.
Publicado: (2022)

Association of TP53 Single Nucleotide Polymorphisms with Prostate Cancer in a Racially Diverse Cohort of Men
por: Duncan, Allison, et al.
Publicado: (2023)

Loss of the NKX3.1 tumorsuppressor promotes the TMPRSS2-ERG fusion gene expression in prostate cancer
por: Thangapazham, Rajesh, et al.
Publicado: (2014)

ERG Tumor Type is Less Frequent in High Grade and High Stage Prostate Cancers of Chinese Men
por: Baohong, Jiang, et al.
Publicado: (2019)

Prostate Cancer Genomics: Recent Advances and the Prevailing Underrepresentation from Racial and Ethnic Minorities
por: Tan, Shyh-Han, et al.
Publicado: (2018)

Germline mutation landscape of DNA damage repair genes in African Americans with prostate cancer highlights potentially targetable RAD genes
por: Kohaar, Indu, et al.
Publicado: (2022)

A novel genomic alteration of LSAMP associates with aggressive prostate cancer in African American men
por: Petrovics, Gyorgy, et al.
Publicado: (2015)

Multi-omic serum biomarkers for prognosis of disease progression in prostate cancer
por: Kiebish, Michael A., et al.
Publicado: (2020)

Age and Tumor Differentiation-Associated Gene Expression Based Analysis of Non-Familial Prostate Cancers
por: Sharad, Shashwat, et al.
Publicado: (2021)

Loss of miR-449a in ERG-associated prostate cancer promotes the invasive phenotype by inducing SIRT1
por: Kumar, Parameet, et al.
Publicado: (2016)

Analysis of PMEPA1 Isoforms (a and b) as Selective Inhibitors of Androgen and TGF-β Signaling Reveals Distinct Biological and Prognostic Features in Prostate Cancer
por: Sharad, Shashwat, et al.
Publicado: (2019)

Long noncoding RNA-mediated activation of androgen receptor in prostate cancer
por: Petrovics, Gyorgy, et al.
Publicado: (2014)

ETS Related Gene mediated Androgen Receptor Aggregation and Endoplasmic Reticulum Stress in Prostate Cancer Development
por: Sreenath, Taduru L., et al.
Publicado: (2017)

Erratum: ETS Related Gene mediated Androgen Receptor Aggregation and Endoplasmic Reticulum Stress in Prostate Cancer Development
por: Sreenath, Taduru L., et al.
Publicado: (2017)

Ets Family Protein, Erg Expression in Developing and Adult Mouse Tissues by a Highly Specific Monoclonal Antibody
por: Mohamed, Ahmed A., et al.
Publicado: (2010)

A Rich Array of Prostate Cancer Molecular Biomarkers: Opportunities and Challenges
por: Kohaar, Indu, et al.
Publicado: (2019)

ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification
por: Furusato, B, et al.
Publicado: (2010)

Prostate cancer gene expression signature of patients with high body mass index
por: Sharad, Shashwat, et al.
Publicado: (2010)

Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population
por: Petrovics, Gyorgy, et al.
Publicado: (2018)

Analytical platform evaluation for quantification of ERG in prostate cancer using protein and mRNA detection methods
por: He, Jintang, et al.
Publicado: (2015)

Proteomic Tissue-Based Classifier for Early Prediction of Prostate Cancer Progression
por: Gao, Yuqian, et al.
Publicado: (2020)

Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia
por: Kiebish, Michael A., et al.
Publicado: (2021)

PMEPA1 Gene Isoforms: A Potential Biomarker and Therapeutic Target in Prostate Cancer
por: Sharad, Shashwat, et al.
Publicado: (2020)

Reconstitution of the ERG Gene Expression Network Reveals New Biomarkers and Therapeutic Targets in ERG Positive Prostate Tumors
por: Dubovenko, Alexey, et al.
Publicado: (2015)

Clinical Validation of a Serum Protein Panel (FLNA, FLNB and KRT19) for Diagnosis of Prostate Cancer
por: Ravipaty, Shobha, et al.
Publicado: (2017)

New Selective Inhibitors of ERG Positive Prostate Cancer: ERGi-USU-6 Salt Derivatives
por: Eldhose, Binil, et al.
Publicado: (2021)

Systematic analysis reveals molecular characteristics of ERG-negative prostate cancer
por: Xiao, Qingyu, et al.
Publicado: (2018)

An expanded biomarker panel for the detection of prostate cancer from urine DNA
por: Brikun, Igor, et al.
Publicado: (2019)

Immunologic Assessment of Tumors from a Race-matched Military Cohort Identifies Mast Cell Depletion as a Marker of Prostate Cancer Progression
por: Schafer, Cara C., et al.
Publicado: (2023)

Increased Smad3 and reduced Smad2 levels mediate the functional switch of TGF-β from growth suppressor to growth and metastasis promoter through TMEPAI/PMEPA1 in triple negative breast cancer
por: Singha, Prajjal K., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_59vh234t4v7h6lfcd7urt22o35